Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort - PubMed
4 hours ago
- #bone metastases
- #apalutamide
- #prostate cancer
- Study evaluates cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients with ≥10 bone metastases treated with apalutamide in a real-world setting.
- Patients with ≥10 bone metastases had higher PSA levels at treatment start (254 vs. 29 ng/ml) and less PSA response (PSA nadir 0.64 vs. 0.03 ng/ml) compared to those with <10 metastases.
- No significant difference in time to metastatic castration-resistant prostate cancer (ttCRPC) was observed between groups (32 vs. 37 months, p=0.15).
- Overall survival (OS) was significantly shorter for patients with ≥10 bone metastases (29 vs. 64 months, HR: 2.5, p=0.02), even after multivariable adjustments.
- Apalutamide showed numerically longer median ttCRPC (32 months) compared to abiraterone (18 months) and docetaxel (16 months) in patients with ≥10 bone metastases.
- Conclusion: Apalutamide-treated mHSPC patients with high bone metastatic burden achieve similar ttCRPC outcomes as those with lower burden, with potential advantages over other treatments.